Pertuzumab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-PERTUZUMAB |
|---|---|
| Type | Drug |
| Aliases | PerjetaПертузумаб |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | HER2-targeted monoclonal antibody (subdomain II / dimerization inhibitor) |
|---|---|
| Mechanism | Binds HER2 subdomain II, blocking HER2:HER3 heterodimerization — complementary mechanism to trastuzumab (which binds subdomain IV). Combination dual-blockade is synergistic. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
APHINITY: improved iDFS in adjuvant high-risk HER2+. CLEOPATRA: improved OS in metastatic 1L (THP). Always combined with trastuzumab — no monotherapy role.
Used By
Regimens
REG-HP-MAINTENANCE- Trastuzumab + Pertuzumab (HP) maintenance, HER2+ metastatic breast post-THP inductionREG-TCHP-NEOADJUVANT- TCHP — docetaxel + carboplatin + trastuzumab + pertuzumab (HER2+ neoadjuvant)REG-THP-METASTATIC- THP — docetaxel + trastuzumab + pertuzumab (HER2+ metastatic 1L)